Overcast 34°
Tag:

Vaccine Research

Business
COVID-19: Pfizer Launches Clinical Trial For Vaccine Targeting Omicron Variant COVID-19: Pfizer Launches Clinical Trial For Vaccine Targeting Omicron Variant
Covid-19: Pfizer Launches Clinical Trial For Vaccine Targeting Omicron Variant New York-based Pfizer and its European partner BioNTech have launched a clinical study to evaluate a COVID-19 vaccine that specifically targets the Omicron variant. The study will evaluate the safety and efficacy of an Omicron-based vaccine among healthy adults ages 18 through 55, Pfizer announced on Tuesday, Jan. 25. According to a recent update from the Centers for Disease Control and Prevention (CDC), the Omicron variant is estimated to have accounted for 99.5 percent of circulating variants of COVID-19 in the United States between Sunday, Jan. 9, and Saturday, Jan. 15. Pfizer said up t…

SHARE

by Nicole Valinote
News
COVID-19: New Studies Shed Light On Moderna Vaccine's Effectiveness Against Variants COVID-19: New Studies Shed Light On Moderna Vaccine's Effectiveness Against Variants
Covid-19: New Studies Shed Light On Moderna Vaccine's Effectiveness Against Variants Researchers have found that the Moderna COVID-19 vaccine has proven effective in fighting off more contagious variants of the virus. A pair of new studies found that the Moderna vaccine, which is one of three approved by the FDA for administration in the U.S., is effective against the California variant that has recently been rapidly spreading, with protection lasting for at least six months. In one study, researchers from Duke University found that antibodies generated by the Moderna dose had approximately two times less neutralizing power against the California strain. While it showed a …

SHARE

by Zak Failla
News
COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective
Covid-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective More reliable than the flu shot? Pfizer on Monday trumpeted a COVID-19 vaccine candidate as more than 90% effective – nearly three times better than the effectiveness of last season’s influenza vaccine. Pfizer said it hopes to have 50 million doses of the free vaccine ready by the end of this year and as many as 1.3 billion doses available next year to fight the deadly global pandemic. Two doses per person of BNT162b2 would be necessary, said the Manhattan-based drug maker, which teamed up with BioNTech of Germany to develop the booster. Pfizer plans to ask the federal Food and Drug Admini…

SHARE

by Jerry DeMarco